Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201706-02 Development of Antibody for Treatment of Dementia(CNS Diseases, Protein) [2019-05-27]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

As a result of the recurrent failure of clinical trials of beta amyloid target antibody treatment candidates as a treatment for Alzheimer's disease, we intend to develop a therapeutic agent for tau target antibodies. In particular, we are trying to derive clinical candidates through an antibody optimization process to develop an antibody (ADEL-Y01) targeting the tau epitope of a certain modified form.

Unmet Medical Need & Target Patients

1. Target patient group

- Various tauopathies including Alzheimer's disease, primary age-related tauopathy, progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia, etc.

 

2. Unmet medical demand

- Due to the failure of clinical trials of candidates for beta amyloid target treatment, there is an increase in demand for global pharmaceutical companies to acquire candidates for tau target treatment.

Status

1. Tau transgenic mice were injected with various treatment candidate epitopes, and the target epitope with the best memory-improving effect was selected and the antibody screening was performed, which derives the ADEL-Y01m antibody.

2. ADEL-Y01m antibody was administered to Tau transgenic mice to confirm memory recovery effect in various behavioral tests and to improve neuropathology.

3. Antibody optimization process is under way through this project.

Intellectual Property

Unpublished

Competitive Advantages

- Tau targeted as the most potent candidate for treatment following beta amyloid failure.

- For this reason, demand from global pharmaceutical companies for securing tau target substances is high.

- Epitope selected with the best therapeutic effect among the various therapeutic candidate epitopes.

- Development of vaccines and development of diagnostic kits enables faster profit generation.

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code